Of 1,000 pregnant women, one to two will experience venous thromboembolism (VTE) during pregnancy or the postpartum period. Pulmonary embolism (PE) is a leading cause of maternal mortality and deep […]» Read more
Women with inherited bleeding disorders, including carriers of hemophilia A and B, or with von Willebrand disease, have an increased risk of bleeding during pregnancy and delivery. Also the unborn […]» Read more
Management of symptoms and prevention of life-threatening haemorrhage in Immune thrombocytopenia (ITP) must be balanced against adverse effects of available therapies. Since current treatment guidelines based on platelet count are […]» Read more
Efficacy of minimal residual disease driven immune-intervention after allogeneic hematopoietic stem cell transplantation for high-risk chronic lymphocytic leukemia: results of a prospective multicentric trial.
Allogeneic hematopoietic stem cell transplantation (HSCT) remains a potentially curative and useful strategy in high-risk relapsing CLL. Minimal Residual Disease (MRD) assessment at 12 months post-HSCT is predictive of relapse. […]» Read more
Kreuth V initiative: European consensus proposals for treatment of haemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies.
This report contains the updated consensus recommendations for optimal haemophilia care produced in 2019 by three Working Groups (WG) on behalf of European Directorate for Quality of Medicines & Healthcare […]» Read more
Thrombosis in Patients with Myeloma Treated in the Myeloma IX and Myeloma XI Phase III Randomized Controlled Trials.
Newly diagnosed multiple myeloma (NDMM) patients treated with immunomodulatory drugs (IMiDs) are at high venous thrombosis (VTE) risk, but data are lacking from large prospective cohorts. We present thrombosis outcome […]» Read more
Recognition that germline mutations can predispose individuals to blood cancers, often presenting as secondary leukemias, has largely been driven in the last 20 years by studies of families with inherited […]» Read more
Acquired hemophilia A (AHA), a rare bleeding disorder caused by neutralizing autoantibodies against coagulation factor VIII (FVIII), occurs in both men and women without a previous history of bleeding. Patients […]» Read more
The field of malignant hematology has experienced extraordinary advancements with survival rates nearly doubling for some leukemias, lymphomas, myeloid malignancies and plasma cell dyscrasias in the past few decades. Five-year […]» Read more
The SARS-CoV-2 coronavirus (COVID-19) induced infection can be associated with a coagulopathy, findings consistent with infection induced inflammatory changes as observed in patients with disseminated intravascular coagulopathy (DIC). The lack […]» Read more
Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model.
Considerable inter- and intra-patient variability exist in serum activity levels of PEGasparaginase, essential for pediatric acute lymphoblastic leukemia treatment. A population pharmacokinetic (popPK) model was developed, identifying patient characteristics explaining […]» Read more
Lupus anticoagulants (LA) are heterogeneous antibodies and no single assay will detect every LA. Consequently, testing is commonly undertaken with both dilute Russell’s viper venom time (dRVVT) and LA-responsive activated […]» Read more
In the ISCHEMIA-CKD trial, the primary analysis showed no significant difference in the risk of death or myocardial infarction with initial angiography and revascularization plus guideline-based medical therapy (invasive strategy) […]» Read more
Recent guidelines recommend consideration of the use of oral edoxaban or rivaroxaban for the treatment of venous thromboembolism in patients with cancer. However, the benefit of these oral agents is […]» Read more
Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report.
Based on the profile of genetic alterations occurring in tumor samples from selected diffuse-large-B-cell-lymphoma (DLBCL) patients, two recent whole exome sequencing studies proposed partially overlapping classification systems. Using clustering techniques […]» Read more
Erdheim-Chester disease: Consensus recommendations for the evaluation, diagnosis, and treatment in the molecular era.
Erdheim-Chester disease (ECD) is a rare histiocytosis that was recently recognized as a neoplastic disorder owing to the discovery of recurrent activating MAP-kinase (RAS-RAF-MEK-ERK) pathway mutations. Typical findings of ECD […]» Read more
Prognostic factors for VTE and Bleeding in Hospitalized Medical Patients: a systematic review and meta-analysis.
Many predictors for venous thromboembolism (VTE) and bleeding in hospitalized medical patients may exist but until now systematic reviews and assessments of the certainty of the evidence do not exist. […]» Read more
EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk-stratification and management.
Epstein Barr virus-positive (EBV+) diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) is an entity included in the 2016 WHO classification of lymphoid neoplasms. EBV+ DLBCL, NOS, is an […]» Read more
Immune Profile Differences between Chronic GvHD and Late Acute GvHD: Results of the ABLE/PBMTC 1202 Studies.
Human graft-versus-host disease (GvHD) biology beyond 3 months post-hematopoietic stem cell transplantation (HSCT) is complex. The Applied Biomarker in Late Effects of Childhood Cancer (ABLE/PBMTC1202, NCT02067832) study evaluated the immune […]» Read more
Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal.
Mast cell leukemia (MCL), the leukemic manifestation of systemic mastocytosis (SM), is characterized by leukemic expansion of immature mast cells (MCs) in the bone marrow (BM) and other internal organs; […]» Read more
Association of Isolated Diastolic Hypertension as Defined by the 2017 ACC/AHA Blood Pressure Guideline With Incident Cardiovascular Outcomes.
In the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) guideline, the definition of hypertension was lowered from a blood pressure (BP) of greater than or equal to 140/90 […]» Read more
Preclinical development of a humanized chimeric antigen receptor against B cell maturation antigen for multiple myeloma.
Multiple myeloma is a prevalent and incurable disease, despite the development of new and effective drugs. The recent development of chimeric antigen receptor (CAR)-T cell therapy has shown impressive results […]» Read more
Venous thromboembolism (VTE) is rare in healthy children,but an increasing problem in children with underlying medical conditions. Pediatric VTE encompasses a highly heterogenous population, with variation in age, thrombosis location […]» Read more
Venous thrombosis rarely occurs at unusual sites such as cerebral, splanchnic, upper extremity, renal, ovarian or retinal veins. Clinical features, symptoms and risk factors of rare thrombotic manifestations are heterogeneous […]» Read more
Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia.
Core-binding factor acute myeloid leukemia is characterized by t(8;21) or inv(16) and the fusion proteins RUNX1-RUNX1T1 and CBFB-MYH11. International guidelines recommend monitoring for measurable residual disease every 3 months for […]» Read more
Immune Thrombocytopenia (ITP) is the commonest acquired thrombocytopenia after chemotherapy-induced thrombocytopenia. Existing guidelines describe the management and treatment of most patients who overall do well, even if they present with […]» Read more
Effect of Fibrinogen Concentrate vs Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery: The FIBRES Randomized Clinical Trial.
Abstract: Excessive bleeding is a common complication of cardiac surgery. An important cause of bleeding is acquired hypofibrinogenemia (fibrinogen level <1.5-2.0 g/L), for which guidelines recommend fibrinogen replacement with cryoprecipitate […]» Read more
Preventing Infectious Complications When Treating Non-Malignant Immune-Mediated Hematologic Disorders.
Abstract: Immunosuppressants, targeted antibody therapies, and surgical splenectomy are amongst the treatment choices for immune-mediated non-malignant hematologic disorders, with infection being the most common non-hematological adverse event from these therapies. […]» Read more
Measurable Residual Disease Monitoring in Acute Myeloid Leukemia with t(8;21)(q22;q22.1): Results of the AML Study Group.
Abstract: We performed serial measurable residual disease (MRD) monitoring in bone marrow (BM) and peripheral blood (PB) samples of 155 intensively treated patients with RUNX1-RUNX1T1-positive AML using an RT-qPCR-based assay […]» Read more
Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the acute leukemia working party of the EBMT.
Abstract: Donor lymphocyte infusion has been used in the management of relapsed disease hematological malignancies after allogeneic hematopoietic cell transplantation. It can eradicate minimal residual disease or be used to […]» Read more